Owned and operated by Baba Kahn, a CF veteran 
BPC-157 vs ARA-290: what is the difference? Both are small peptides that scientists study for healing. But they come from very different places, and they seem to work in different ways. So this guide uses easy words and lots of pictures to explain both.
- 15 vs 11 building blocks
- 1993 vs 2008 first described
- 0 approved medicines
- 11 easy pictures
When people compare BPC-157 vs ARA-290, the first thing to know is simple. Both are peptides. A peptide is a short chain of tiny parts called amino acids.
BPC-157 is based on a protein found in stomach juice. It has 15 amino acids. Most of its research is on rats, and labs study it for tendons, muscles and the gut.
ARA-290 is a tiny copy of one part of EPO, a hormone made by the kidneys. It has 11 amino acids. Unlike BPC-157, it has been tested in a few small studies in people, mostly for nerve pain.
Still, neither one is an approved medicine. In Canada, Red Leaf sells BPC-157 10mg and ARA-290 10mg as dry powders for lab research. An outside lab also tests every batch.
What is a peptide?
Think of a peptide like a short bracelet of beads. Each bead is an amino acid. Amino acids are the tiny parts that build every protein in your body.
BPC-157 is a bracelet with 15 beads, while ARA-290 has 11 beads. The order of the beads gives each peptide its job. For example, think of the order of letters in a word. When you change the order, you get a new word.
Each letter is the short name of one amino acid. The first ARA-290 bead, pE, is a special ring-shaped bead.
What is BPC-157?
BPC stands for Body Protection Compound. Scientists first found it in human stomach juice. Your stomach is full of strong acid, so anything that lasts in there has to be tough.
In 1993, a team led by Dr. Predrag Sikirić in Zagreb, Croatia, wrote about BPC-157. It is a 15-bead piece of that stomach protein. Today, labs build it from scratch instead, one bead at a time.
Online, some people call BPC-157 the “Wolverine peptide.” However, that is just a nickname. It is not science.
A simple drawing, not to scale. Labs no longer take BPC-157 from stomach juice. They build it bead by bead.
What is ARA-290?
ARA-290 starts with a hormone called EPO. Your kidneys make EPO. Its main job is to tell your body to make more red blood cells, because red blood cells carry oxygen.
Scientists saw that EPO also helps protect hurt cells. But too much EPO makes the blood thick, and thick blood can form clots.
So a team in New York, led by Dr. Michael Brines and Dr. Anthony Cerami, copied one small part of EPO. In 2008, they showed that this small piece could still send the “protect” signal. However, it did not tell the body to make more red blood cells. That piece became ARA-290. Its drug name is cibinetide.
A simple drawing, not to scale. The switches show what scientists reported in lab and animal studies.
How do BPC-157 and ARA-290 work?
Scientists are still learning how both peptides work. So here is what lab and animal studies point to, in plain words.
BPC-157: the road crew
Blood vessels are like roads, because they bring food and oxygen to cells that are trying to heal. In rat studies, BPC-157 seemed to help new tiny blood vessels grow near a hurt spot.
It also seems to work with nitric oxide. That is a gas the body uses to open up blood vessels.
ARA-290: the repair button
ARA-290 fits a lock on the outside of some cells. The lock is called the innate repair receptor, so think of it as a repair button.
When ARA-290 presses the button, cells send fewer swelling signals. Swelling is your body’s alarm system. A little is helpful, but too much for too long can hurt nerves and other parts of the body.
A simple picture of ideas from lab and animal studies. Scientists are still checking how both work.
What do labs study them for?
The two peptides are studied for very different things. BPC-157 is mostly about healing tissue, while ARA-290 is mostly about nerves and swelling.
BPC-157 research
Tendons and ligaments
Tendons are strong cords that tie muscles to bones. In rats with cut or torn tendons, the ones given BPC-157 often healed better.
Muscles
Rat studies also looked at muscles that were crushed or cut. Many reported better healing in the BPC-157 group.
Stomach and gut
Since it comes from stomach juice, many studies test it on stomach sores and gut damage in rats.
ARA-290 research
Nerve pain
Small fibre neuropathy means the tiny nerves in the skin get hurt. As a result, it can cause burning pain in the hands and feet. This is the main ARA-290 topic.
Sarcoidosis
Sarcoidosis is a disease where small swollen lumps form in the body, often in the lungs. It can also hurt tiny nerves, so most ARA-290 trials were in this group.
Blood sugar
In a 28-day study of people with type 2 diabetes, the ARA-290 group had better blood sugar numbers and less nerve pain than the dummy group.
Where studies looked, not a list of proven results. BPC-157 work is mostly in rats. ARA-290 has small studies in people.
How much proof is there?
This is the biggest difference in the BPC-157 vs ARA-290 story.
Science has steps, like a ladder. First come cells in a dish. Next come animals, and after that, small studies in people. Big studies in people come last. Only after all that can a medicine be approved.
A medicine has to climb every step before it can be approved. Big studies in people are still missing for both.
BPC-157 is mostly on step 2
A 2025 review looked at BPC-157 research on muscles, tendons and bones. It found 36 studies. Of those, 35 were in animals and only 1 was in people. In all, only about 30 people have been in published BPC-157 reports. Also, none of those reports compared BPC-157 with a dummy group.
ARA-290 has reached step 3
ARA-290 has been tested in a few small studies in people. Some were fair tests with a dummy group. The biggest had 64 people with nerve pain from sarcoidosis. After 28 days, one group had more tiny nerve fibres in the eye. Doctors can count those nerves with a special camera.
But these studies were small and short, and small studies can be wrong. That is why big studies are still needed for both peptides.
Some ARA-290 studies were fair tests like this. The published BPC-157 reports in people were not.
How long do they last in the body?
Peptides do not last long in the blood, because the body breaks them down fast. It is a bit like ice melting on a hot day.
Scientists measure this with a number called half-life. Half-life is how long it takes for half of something to be gone. For ARA-290, it is about 2 minutes. For BPC-157, it is under 30 minutes in rats.
Here is the odd part. In studies, the effects of ARA-290 seemed to last much longer than that. Scientists think it flips a switch inside cells, and then the switch stays on for a while.
This time is called the half-life. Rounded numbers from published studies.
BPC-157 vs ARA-290, side by side
Here is everything in one table.
| BPC-157 | ARA-290 | |
|---|---|---|
| Where it comes from | A protein in stomach juice | EPO, a hormone made by the kidneys |
| Number of amino acids | 15 | 11 |
| First described | 1993, Croatia | 2008, New York |
| Other names | PL 14736, bepecin | Cibinetide, pHBSP |
| Main research topic | Tendons, muscles and the gut | Nerve pain and swelling |
| How it seems to work | Helps new blood vessels grow (in rats) | Presses the cell’s repair button |
| Studies in people | 3 tiny reports, about 30 people | A few small trials, up to 64 people |
| Half-life in blood | Under 30 minutes (rats) | About 2 minutes |
| Approved medicine? | No | No |
| Sports (WADA) | Banned by name | Its group is banned |
| At Red Leaf | 10mg vial, lab tested | 10mg vial, lab tested |
Save or share this picture. Research use only. Not medical advice.
Are BPC-157 and ARA-290 legal in Canada?
Canada’s rule is simple. A medicine needs Health Canada’s OK before it can be sold for people to use. For BPC-157 vs ARA-290, the answer is the same: neither one has that OK.
Back in April 2026, Health Canada warned Canadians not to buy peptide drugs online to inject. BPC-157 was on its list of examples. Health Canada also said that a “research use only” label does not make a product legal to use on people.
South of the border, an FDA expert panel voted 8 to 6 in July 2026 to let special pharmacies make BPC-157. Still, the FDA has not made a final decision. That vote also does not change the rules in Canada.
Sports have their own rules. The World Anti-Doping Agency (WADA) bans BPC-157 by name. ARA-290 is not named, but WADA bans its whole group, called innate repair receptor agonists. So athletes who get tested should stay away from both.
In July 2026 a US FDA panel voted to let special pharmacies make BPC-157. That is not an approval, and the FDA has not decided yet.
How to check BPC-157 and ARA-290 quality
Not every vial is what it says. Use these five checks before you buy.
- Look for a lab report. A good seller shows a test from an outside lab for each batch. It is often called a COA, and Red Leaf posts one for every batch. See how our testing works.
- Match the name and amount. The label and the lab report should show the same peptide and the same amount, like 10mg.
- Check the purity number. Purity shows how much of the powder is the real peptide, so higher is better.
- Look at the powder. Both should be a dry, white powder or small cake inside a sealed glass vial.
- Buy in Canada. A Canadian seller means no border delays and no surprise fees. For example, Red Leaf ships express from Ontario.
How to store BPC-157 and ARA-290
Peptide powder is a bit like ice cream, because heat, water and light can ruin it. So keep it cold, dry and dark.
Both Red Leaf labels say: store at -20°C.
More guides on these peptides
- BPC-157 in Canada: legal status, safety and evidence
- BPC-157 vs TB-500: the key differences
- ARA-290 research guide
- IBS in Canada and what gut peptides do
- Herniated disc treatment in Canada, with BPC-157 research
- 25 peptide myths, busted: take the quiz
BPC-157 and ARA-290 in our shop
Every vial ships with an outside lab report you can check online.
Questions people ask
What is the difference between BPC-157 and ARA-290?
The main BPC-157 vs ARA-290 difference is where they come from and how much proof there is. BPC-157 is a 15-amino-acid peptide based on a protein in stomach juice, and it is studied mostly in rats for tendons, muscles and the gut. ARA-290 is an 11-amino-acid peptide copied from one part of EPO, a kidney hormone. It has been tested in small human studies, mostly for nerve pain. Neither one is an approved medicine.
Where does BPC-157 come from?
BPC stands for Body Protection Compound. It was first found in human stomach juice. Then, in 1993, a team in Zagreb, Croatia, wrote about BPC-157, a 15-bead piece of it. Today labs build it from scratch instead.
Where does ARA-290 come from?
ARA-290 is a tiny copy of one part of EPO, a hormone made by the kidneys. Scientists in New York described it in 2008. Its drug name is cibinetide.
Is ARA-290 the same as EPO?
No. EPO tells the body to make more red blood cells. ARA-290 is a small piece of EPO that kept the protect-the-cells signal. However, in studies it did not make more red blood cells.
Which one has more studies in people?
ARA-290, because it has been tested in a few small studies in people, some with a dummy group for a fair test. By contrast, BPC-157 has only three tiny reports in people, with about 30 people in total and no dummy group.
Are BPC-157 and ARA-290 approved in Canada?
No. Health Canada has not approved either one as a medicine. Also, in April 2026, Health Canada warned Canadians not to buy peptide drugs online to inject, and BPC-157 was on its list.
Are BPC-157 and ARA-290 banned in sports?
Yes. The World Anti-Doping Agency bans BPC-157 by name. ARA-290 is not named, but WADA bans its whole group, called innate repair receptor agonists.
How should BPC-157 and ARA-290 powder be stored?
Keep the sealed vials cold, dry and dark, because heat, water and light can harm the powder. Both Red Leaf labels say to store them at -20°C, which is a normal home freezer.
Every Red Leaf vial carries an independent lab report with a verify link, right on the product page. Free express shipping on Canadian orders over $250.
BPC-157 (10mg)ARA-290 (10mg)Browse the full catalogueSources
BPC-157 studies
- Sikirić P, Petek M, Ručman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology (Paris), 1993; 87: 313–327.
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, 2025; 21(4): 485–495. View on PubMed Central
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 2021; 27(4): 8–13.
- Brubaker P. BPC-157: no proof required! McGill University Office for Science and Society, March 13, 2026. Read the article
ARA-290 studies
- Brines M, Patel NSA, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. PNAS, 2008; 105(31): 10925–10930. View on PubMed
- Dahan A, Dunne A, Swartjes M, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular Medicine, 2013; 19: 334–345.
- Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine, 2015; 20(1): 658–666.
- Culver DA, Dahan A, Bajorunas D, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Investigative Ophthalmology & Visual Science, 2017; 58(6): BIO52–BIO60.
- Collino M, Thiemermann C, Cerami A, Brines M. Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacology & Therapeutics, 2015; 151: 32–40.
- European Medicines Agency. Orphan designation EU/3/13/1191 (cibinetide) for the treatment of sarcoidosis, October 7, 2013. View on the EMA website
Rules and news
- Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm your health. Public advisory RA-81874, April 9, 2026. Read the advisory
- ABC News. FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list. July 23, 2026. Read the story
- World Anti-Doping Agency. 2026 Prohibited List: S0 Non-approved substances (BPC-157) and S2.1.5 Innate repair receptor agonists. View the list
Research use only. BPC-157, ARA-290, TB-500 and every other compound named here are sold by Red Leaf Research Labs as laboratory materials for in-vitro research. They are not approved for cosmetic, treatment, injection, ingestion or any human or animal use. Nothing on this page is medical advice, a dose, or a protocol. Study findings are described from published research so readers can see what was measured. Full wording on our legal terms page.
